Literature DB >> 15991911

Duloxetine (LY 248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate.

D T Wong1.   

Abstract

Duloxetine is a potent inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and noradrenaline (NE) uptake in vitro and in vivo and is 3- to 5-times more effective at inhibiting 5-HT uptake. Duloxetine is a weak inhibitor of dopamine (DA) uptake and the binding of radioligands to neurotransmitter receptors. Upon administration of duloxetine in vivo, the inhibitory effects on uptake of 5-HT and NE persist for up to 8 h. Desmethylduloxetine, a potential metabolite, is also an inhibitor of 5-HT and NE uptake. Consistent with the ability to inhibit the uptake of 5-HT, duloxetine blocks p-chloroamphetamine induced depletion of mouse and rat brain 5-HT. Duloxetine also blocks the 6-hydroxydopamine induced depletion of mouse heart NE and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced depletion of NE in frontal cortex but does not block the MPTP induced depletion of DA in rat striatum. Electrophysiological studies show that duloxetine decreases the activity of 5-HT neurones in dorsal raphe and at a 5-times higher dose also decreases the activity of NE neurones in the locus coeruleus. Microdialysis techniques have demonstrated that duloxetine effectively elevates extracellular 5-HT and NE levels in rat frontal cortex and hypothalamus. Antagonists at somatodendritic 5-HT(1A) autoreceptors or at presynaptic alpha(2)-adrenergic receptors could augment the duloxetine induced elevation of extracellular 5-HT, NE and DA levels. Duloxetine produces behavioural responses consistent with the enhancement of 5-HT and NE neurotransmission. Pharmacokinetic studies in healthy human volunteers show that duloxetine has a half-life of 10 - 15 h without the influence of food. In preliminary clinical trials, duloxetine has shown antidepressive effects in patients with major depression. Duloxetine offers an opportunity to utilise combined central 5-HT and NE neuronal pathways to improve the treatment of patients with major depression.

Entities:  

Year:  1998        PMID: 15991911     DOI: 10.1517/13543784.7.10.1691

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  10 in total

1.  A dose-finding study of duloxetine based on serotonin transporter occupancy.

Authors:  Akihiro Takano; Kazutoshi Suzuki; Jun Kosaka; Miho Ota; Shoko Nozaki; Yoko Ikoma; Shuji Tanada; Tetsuya Suhara
Journal:  Psychopharmacology (Berl)       Date:  2006-02-28       Impact factor: 4.530

2.  Antidepressants but not antipsychotics have antiepileptogenic effects with limited effects on comorbid depressive-like behaviour in the WAG/Rij rat model of absence epilepsy.

Authors:  Rita Citraro; Antonio Leo; Pasquale De Fazio; Giovambattista De Sarro; Emilio Russo
Journal:  Br J Pharmacol       Date:  2015-04-10       Impact factor: 8.739

3.  Serotonin, β-amyloid, and cognition in Parkinson disease.

Authors:  Vikas Kotagal; Cathie Spino; Nicolaas I Bohnen; Robert Koeppe; Roger L Albin
Journal:  Ann Neurol       Date:  2018-05-11       Impact factor: 10.422

4.  The role of duloxetine in the treatment of anxiety disorders.

Authors:  Domenico De Berardis; Nicola Serroni; Alessandro Carano; Marco Scali; Alessandro Valchera; Daniela Campanella; Alessandro D'Albenzio; Berardo Di Giuseppe; Francesco Saverio Moschetta; Rosa Maria Salerno; Filippo Maria Ferro
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

Review 5.  Continuation treatment of major depressive disorder: is there a case for duloxetine?

Authors:  Trevor R Norman; James S Olver
Journal:  Drug Des Devel Ther       Date:  2010-02-18       Impact factor: 4.162

6.  Brain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in rats.

Authors:  Katsumasa Muneoka; Yukihiko Shirayama; Morikuni Takigawa; Seiji Shioda
Journal:  Neurochem Res       Date:  2008-08-27       Impact factor: 3.996

7.  A Dual Noradrenergic Mechanism for the Relief of Neuropathic Allodynia by the Antidepressant Drugs Duloxetine and Amitriptyline.

Authors:  Mélanie Kremer; Ipek Yalcin; Yannick Goumon; Xavier Wurtz; Laurent Nexon; Dorothée Daniel; Salim Megat; Rhian A Ceredig; Carl Ernst; Gustavo Turecki; Virginie Chavant; Jean-François Théroux; Adrien Lacaud; Lauriane-Elisabeth Joganah; Vincent Lelievre; Dominique Massotte; Pierre-Eric Lutz; Ralf Gilsbach; Eric Salvat; Michel Barrot
Journal:  J Neurosci       Date:  2018-09-24       Impact factor: 6.167

8.  Duloxetine in the treatment of generalized anxiety disorder.

Authors:  Trevor R Norman; James S Olver
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

9.  Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study.

Authors:  Cédric M Hysek; Linda D Simmler; Valentina G Nicola; Nerina Vischer; Massimiliano Donzelli; Stephan Krähenbühl; Eric Grouzmann; Jörg Huwyler; Marius C Hoener; Matthias E Liechti
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

10.  Item-based analysis of the effects of duloxetine in depression: a patient-level post hoc study.

Authors:  Alexander Lisinski; Fredrik Hieronymus; Jakob Näslund; Staffan Nilsson; Elias Eriksson
Journal:  Neuropsychopharmacology       Date:  2019-09-14       Impact factor: 7.853

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.